The 36-month beta value for TGTX is also noteworthy at 2.24. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for TGTX is 140.42M, and at present, short sellers hold a 22.79% of that float. The average trading volume of TGTX on November 27, 2024 was 3.76M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TGTX) stock’s latest price update
The stock price of TG Therapeutics Inc (NASDAQ: TGTX) has plunged by -1.01 when compared to previous closing price of 34.61, but the company has seen a 12.99% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-21 that NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year.
TGTX’s Market Performance
TG Therapeutics Inc (TGTX) has seen a 12.99% rise in stock performance for the week, with a 40.70% gain in the past month and a 46.72% surge in the past quarter. The volatility ratio for the week is 7.56%, and the volatility levels for the past 30 days are at 8.07% for TGTX. The simple moving average for the past 20 days is 14.64% for TGTX’s stock, with a 72.06% simple moving average for the past 200 days.
Analysts’ Opinion of TGTX
Many brokerage firms have already submitted their reports for TGTX stocks, with TD Cowen repeating the rating for TGTX by listing it as a “Buy.” The predicted price for TGTX in the upcoming period, according to TD Cowen is $50 based on the research report published on October 29, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see TGTX reach a price target of $12, previously predicting the price at $16. The rating they have provided for TGTX stocks is “Neutral” according to the report published on August 02nd, 2023.
Jefferies gave a rating of “Buy” to TGTX, setting the target price at $40 in the report published on June 26th of the previous year.
TGTX Trading at 31.81% from the 50-Day Moving Average
After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.00% of loss for the given period.
Volatility was left at 8.07%, however, over the last 30 days, the volatility rate increased by 7.56%, as shares surge +33.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.60% upper at present.
During the last 5 trading sessions, TGTX rose by +12.99%, which changed the moving average for the period of 200-days by +125.69% in comparison to the 20-day moving average, which settled at $29.88. In addition, TG Therapeutics Inc saw 100.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TGTX starting from Lonial Sagar, who sale 5,000 shares at the price of $30.44 back on Nov 11 ’24. After this action, Lonial Sagar now owns 100,195 shares of TG Therapeutics Inc, valued at $152,200 using the latest closing price.
Charney Laurence N, the Director of TG Therapeutics Inc, sale 25,000 shares at $30.20 during a trade that took place back on Nov 11 ’24, which means that Charney Laurence N is holding 212,479 shares at $754,875 based on the most recent closing price.
Stock Fundamentals for TGTX
Current profitability levels for the company are sitting at:
- -0.0 for the present operating margin
- 0.88 for the gross margin
The net margin for TG Therapeutics Inc stands at -0.05. The total capital return value is set at -0.0. Equity return is now at value -8.05, with -3.13 for asset returns.
Based on TG Therapeutics Inc (TGTX), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -0.12. The debt to equity ratio resting at 1.27. The interest coverage ratio of the stock is -0.03.
Currently, EBITDA for the company is 26.1 million with net debt to EBITDA at 9.85. When we switch over and look at the enterprise to sales, we see a ratio of 20.36. The receivables turnover for the company is 2.29for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.
Conclusion
In summary, TG Therapeutics Inc (TGTX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
